Fortress Biotech, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases
Fortress Biotech, Inc. (FBIO) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases of $9.91 million for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-18.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases · last filed 2019-03-18
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2016-12-31 was $13.16M.
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2016-09-30 was $4.83M.
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2017 was $9.91M, a 48.06% decline from fiscal 2016.
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2016 was $19.09M, a 6505.19% increase from fiscal 2015.
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2015 was $289.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 12 month |
|---|---|---|---|---|
| 2017-12-31 | $9.91M 10-K · filed 2019-03-18 | |||
| 2016-12-31 | $13.16M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $17.99M derived: sum of 2 quarters · filed 2018-03-16 | $19.09M 10-K · filed 2018-03-16 | |
| 2016-09-30 | $4.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $5.93M 10-Q · filed 2016-11-09 | ||
| 2016-06-30 | $1.10M 10-Q · filed 2016-08-09 | |||
| 2015-12-31 | $289.00K 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |